











































Donor insulin use predicts betacell function after islet
transplantation
Citation for published version:
Shapey, IM, Summers, A, Yiannoullou, P, Khambalia, H, Fullwood, C, Hanley, NA, Casey, J, Forbes, S,
Rosenthal, M, Johnson, P, Choudhary, P, Bushnell, J, Shaw, JA, Augustine, T, Rutter, MK & Van Dellen, D
2020, 'Donor insulin use predicts betacell function after islet transplantation', Diabetes, Obesity and
Metabolism. https://doi.org/10.1111/dom.14088
Digital Object Identifier (DOI):
10.1111/dom.14088
Link:




Diabetes, Obesity and Metabolism
Publisher Rights Statement:
this is the accepted authors manuscript
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.






Donor insulin use predicts beta-cell function after islet transplantation 
Authors: Iestyn M Shapey PhD MRCS 
1,2#
, Angela Summers BSc(Hons) PhD
1,2
, Petros Yiannoullou 
MBBS MRCS
1,2
, Hussein Khambalia PhD FRCS
1,2
, Catherine Fullwood PhD
1,3
, Neil A Hanley MBChB 
PhD FRCP
1
, John Casey MBChB PhD FRCS FRCP
4
, Shareen Forbes MBChB PhD FRCP
4,5
, 
Miranda Rosenthal PhD FRCP
6
, Paul RV Johnson MBChB MD FRCS
7
, Pratik Choudhary MBBS PhD 
FRCP
8
, James Bushnell MD MRCP
9
, James AM Shaw MBChB PhD FRCP
10
, Titus Augustine MS 
FRCS
1,2
, Martin K Rutter MD FRCP
1,11*
, David van Dellen MD FRCS
1,2* 
 
*Equal contribution  
Institutions 
1) Faculty of Medicine, Biology and Health, University of Manchester, Manchester, M13 9PL UK. 
2) Department of Renal and Pancreatic Transplantation, Manchester University NHS Foundation 
Trust, Manchester Academic Health Science Centre, Manchester, M13 9WL UK 
3) Department of Research and Innovation (medical statistics), Manchester University NHS 
Foundation Trust, Manchester Academic Health Science Centre, Manchester, M13 9WL, UK 
4) Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, UK 
5) Endocrinology Unit, University of Edinburgh, Edinburgh, EH16 4TJ UK, 
6) Diabetes Unit, Royal Free Hospital, London, NW3 2QG, UK 
7) Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, 
OX3 7LE, UK 
8) Diabetes Research Group, King’s College London, London, SE5 9RJ, UK 
9) Richard Bright Renal Unit, Southmead Hospital, Bristol, BS10 5NB UK 
10) Institute of Cellular Medicine, Newcastle University, Newcastle, NE2 4HH UK 
11) Manchester Diabetes Centre, Manchester University NHS Foundation Trust, Manchester 
Academic Health Science Centre, Manchester, M13 0JE, UK 
 
 
Keywords: Organ donor; insulin; pancreas; islet; transplant 
Word count: 1942 
Article type: Brief report 
Funding: 
1) Medical Research Council  
2) Royal College of Surgeons of Edinburgh 







Author contribution:  
IMS - all aspects of the study, lead author 
AS - all aspects of the study, but not data collection 
PY – data collection, data interpretation, writing 
HK - data collection, data interpretation, writing 
CF - data analysis, statistical oversight, writing 
NAH - study concept & oversight, writing 
JC - chair of pancreas advisory group at NHS Blood and Transplant with oversight over national data 
collection; writing  
SF  - Principal Investigator (Edinburgh); writing 
MR – Principal Investigator (Royal Free, London), writing 
PRVJ – Principal Investigator (Oxford), writing 
PC – Principal Investigator (Kings College, London), writing 
JB – Principal Investigator (Bristol), writing 
JAMS – Chair of the UK Islet Transplant Consortium, Principal Investigator (Newcastle), writing 
TA - deputy chair of pancreas advisory group at NHS Blood and Transplant with oversight over 
national data collection; study concept & oversight; writing 
MKR - all aspects of the study, senior author 








Insulin is routinely used to manage hyperglycaemia in organ donors and during the peri-transplant 
period in islet transplant recipients. However, it is unknown whether Donor Insulin Use (DIU) predicts 
beta-cell dysfunction after islet transplantation.  We reviewed data from the United Kingdom (UK) 
Transplant Registry and the UK Islet Transplant Consortium – all first-time transplants between 2008-
2016 were included.  Linear regression models determined associations between DIU, median and 
coefficient of variation (CV) peri-transplant glucose levels and 3-month islet graft function.  In 91 islet 
cell transplant recipients, DIU was associated with lower islet function assessed by BETA-2 scores (β 
[SE] -3.5 [1.5], p=0.02), higher 3-month post-transplant HbA1c levels (5.4 [2.6] mmol/mol, p=0.04) 
and lower fasting c-peptide levels (-107.9 [46.1] pmol/l, p=0.02).  Glucose at 10,512 time points were 
recorded during the first 5 days peri-transplant - the median (IQR) daily glucose level was 7.9 (7.0-
8.9) mmol/L and glucose CV: 28 (21-35)%.  Neither median glucose levels nor glucose CV predicted 
outcomes post-transplantation. Data on DIU predicts beta-cell dysfunction 3-months after islet 











In patients with type 1 diabetes mellitus (T1DM), islet cell transplantation (ICT) provides an 
opportunity to alleviate life-threatening hypoglycaemia, improve glycaemic control, reduce the 
progression of diabetes related microvascular complications, and in some cases, achieve insulin 
independence.
1,2
 However, the routine attainment of insulin independence after islet transplantation 
from a single donor is unusual thereby prompting efforts to better understand donor selection and to 
improve post-transplant islet graft function.   
Several factors, including higher donor glucose levels, are known to predict poorer outcomes 
after islet isolation
3,4
.  Hyperglycaemia develops in approximately 50% of organ donors and is 
managed with insulin on intensive care units (ICUs). However the relationship between donor insulin 
use (DIU) and outcomes post-transplantation has not been investigated.  The co-administration of 
insulin and heparin during the peri-transplant period has been associated with higher rates of insulin 
independence post-transplantation
5
.  However, there is limited observational data to suggest that 
tighter glycaemic control is associated with better beta cell function post-transplant. 
In this study, we first hypothesized that DIU predicts beta-cell dysfunction after islet 
transplantation and aimed to assess relationships of DIU with islet graft failure and function at 3-
months after transplantation.  Second, we hypothesized that tighter peri-transplant glycaemic control 
would be beneficial, and we aimed to determine the relationship between median levels and the co-
efficient of variation (CV) of glucose levels during the peri-transplant period with measures of beta-cell 











To assess relationships between DIU and islet transplant outcomes, the entire cohort of national data 
(2008-2016) from the UK Islet Transplant Consortium (UKITC) was reviewed. Our acceptance criteria 
for pancreas donors were: age 25-60 years, BMI 25-40 kg/m
2
, and cold ischaemic time <12 hours. 
We excluded donors with known diabetes, and HbA1c values >48 mmol/mol (6.5%).  Only first-time 
islet transplant recipients were included so that the relationships between DIU and glycaemic control 
during the engraftment period and outcomes post-transplantation could be accurately described 
without the potential influence of a prior islet cell transplant.   
 
Peri-donation and peri-transplant glycaemic control 
The UK NHS Blood and Transplant donor care bundle provides standardised guidance to maintain 
donor glucose levels between 4-10 mmol/L, and, at blood glucose levels >10mmol/L, to commence a 
variable rate intravenous insulin infusion at a minimum rate of 1 IU/hour.
6
  DIU was defined as any 
requirement for exogenous insulin during the peri-donation period.  Data on donor insulin dosage is 
not routinely collected but dosage can be estimated from the duration of insulin treatment.  
Procurement of organs from donors in the UK follows a standardised operative procedure in keeping 
with guidance from NHS Blood and Transplant.
7
  Glucose levels during the first 5 days post-
transplantation were obtained from capillary blood glucose and continuous glucose monitoring data.  
The peri-transplant target blood glucose range was 4.0-6.9 mmol/L, and an intensive variable rate 
intravenous insulin therapy regimen was followed for the first 48 hours, and subcutaneous or pump 
insulin therapy thereafter. 
Islet, isolation, assessment and transplantation 
Pancreases were transported at 4°C in University of Wisconsin solution to one of three human islet 
isolation facilities located in Edinburgh, London or Oxford.  Following digestion with Collagenase NB 6 
GMP Grade (Serva, Heidelberg, Germany) and automated mechanical dissociation in a Ricordi 
chamber, islets were purified on a continuous density gradient using a COBE 2991 processor.    Islets 






met: islet mass >3000 IEQ/kg; viability >70%; and purity >50%.  When the allocated recipient was 
located at a different unit to the isolation centre, islets were resuspended in 500mL of CMRL medium 
(PAA Laboratories Ltd, Somerset, UK) supplemented with 2% human serum albumin (ZENLAB20: Bio 
Products Laboratories, Herts, UK) and 2 mM HEPES (PAA Laboratories Ltd, Somerset, UK) and   
transported by road in cooled standard blood transfusion bags.  Islets were transplanted by 
radiological guided percutaneous trans-hepatic infusion into the portal vein. 
Defining graft function and failure 
Graft function was determined by glycosylated haemoglobin (HbA1c), fasting and stimulated glucose 
and c-peptide levels, and the BETA-2 score assessed at 3-months post-transplantation.  The BETA-2 
score is a composite measure of graft function including HbA1c, fasting and 90-minute stimulated c-
peptide, glucose levels, and insulin requirement.
8
  Graft failure was defined as stimulated C-peptide 
<50 pmol/L. 
Analysis 
We assessed the distributions of donor and recipient variables for exposures, covariates and 
outcomes. Univariable and multivariable-adjusted linear regression models explored relationships 
between DIU status and graft function. Multivariable-adjusted models included covariates identified 
through univariable associations with DIU status, and also included covariates widely reported as 
potential confounders.  Linear regression related covariates to median glucose levels and the glucose 
coefficient of variation (CV).  Univariable and multivariable linear regression models related median 
glucose levels and glucose CV to graft function outcomes outlined above.   
Ethical approval 
All data were collected prospectively, with ethical approval (UKITC 07/Q0904/11), and with 









Of the 91 first-time ICT recipients (female: n=40 [44%]; mean [SD] age 50 [10] years), 52 (57%) had a 
donor treated with insulin on ICU. The median (IQR) islet yield was 390 (320-495) x 1000 IEQ and 
median viability was 90 (85-90) %, and purity 75 (70-85) %.  All patients received immunosuppression 
with tacrolimus and mycophenolate, ten of whom also received steroids (in the early years of the 
programme).  Induction therapy with Alemtuzumab (Campath) was given routinely to all patients apart 
from eight (9%) who received Basiliximab (Simulect), and one (1%) who received rabbit Anti-
Thymocyte Globulin.  Seven (8%) patients also received anti-TNF therapy (Etanercept). 
DIU was not significantly associated with any measured donor characteristics that could 
confound relationships between DIU and graft outcomes (Table 1).  Statistically significant 
relationships were demonstrated between DIU and higher 3-month post-transplant HbA1c (mean [SD] 
HbA1c, DIU vs. no-DIU: 50 [2.0] vs. 45 [1.5] mmol/mol, p=0.04), higher fasting and 90-minute 
stimulated glucose (fasting: 9.7 [0.8] vs 7.8 [0.5] mmol/L, p=0.04 and 90-minute: 15.8 [1.0] vs. 12.9 
[0.7] mmol/L, p=0.024); lower fasting c-peptide (191 [20.7] vs 299 [43.9] pmol/L, p=0.02) and a lower 
BETA2 score (7 [0.9] vs 11 [1.2]), p=0.02). These relationships remained significant after adjusting for 
age, BMI and total number of islets transplanted (IEQ/kg) (Table 2)  Rates of graft failure were higher 
in transplants from DIU compared with no-DIU although this was not statistically significant (5/45 vs 
1/41, p=0.22).  In DIU, duration of insulin was not significantly associated with any outcomes. 
Complete data on peri-transplant glucose levels were available from 69 islet transplant 
recipients.  We recorded 10,512 glucose levels (68 [53-88] per patient) during the first 5 days post-
transplant.  The median (IQR) daily glucose level was 7.9 (7.0-8.9) mmol/L and glucose CV was 28 
(21-35) %.  DIU (β [se] 1.17 [0.67], p=0.09) was identified as a nominal covariate of median daily 
glucose levels, whilst donor BMI (-0.66 [0.35], p=0.06) was a nominal covariate of glucose CV 
(Supplementary table 1).    Neither median daily glucose nor the CV of glucose levels were 
significantly related to any measures of graft function at 3 months after islet transplantation 








We have shown that DIU is associated with poorer graft function in ICT recipients.  DIU was 
associated with: a) a lower BETA-2 score 3-months post ICT; b) a higher HbA1c 3-months post ICT; 
c) a higher fasting and 90-minute glucose level 3-months post ICT; and, d) a lower fasting C-peptide 
3-months post ICT.  These data are consistent with our hypothesis that DIU is a predictor of adverse 
outcomes in islet transplantation.   
 
Prior studies 
To the best of our knowledge, this is the first study assessing relationships between DIU and peri-
transplant glycaemic control and measures of graft function in islet-cell transplants recipients.  Two 
relevant studies evaluated the relationship between donor hyperglycaemia and the success of human 
islet isolation and reported conflicting findings.
3,9
  In the smaller study there was no relationship 
between donor hyperglycaemia or insulin use, and success from islet isolation attributed to a higher 
islet yield in the successful preparations.
9
  A larger study involving 153 islet isolations, reported an 
association between lower donor blood glucose levels and successful islet isolation
3
 and led to the 
subsequent inclusion of blood glucose levels in a composite scoring system to assess donor 
pancreases.
4
    
 
Mechanistic insights 
We showed that approximately 50% of organ donors require exogenous insulin on ICU 
because of hyperglycaemia.  DIU could simply be a marker of donor insulin resistance which is well-
documented after brain death, and could be exacerbated by inflammation, inotrope and corticosteroid 
use, and low cardiac output leading to muscle and liver hypo-perfusion.
10–12
  Theoretically, these 
scenarios leading to beta-cell stress would be reversible at the time of organ retrieval when the 
pancreas is removed from the stressors causing donor insulin resistance.  In our data, similar HbA1c 
levels in both the DIU and non-DIU groups suggests that DIU does not occur because of pre-existing 






on ICU occurs as a consequence of a combination of beta-cell stress (donor insulin resistance) and 
beta-cell death.     The alternative scenario that DIU could be explained by beta-cell death requires 
further research.‬‬‬ 
Insulin therapy to treat hyperglycaemia also promotes beta-cell rest
13
.  Therefore, it is 
possible that DIU may have a beneficial effect, especially in donors experiencing severe beta-cell 




Clinicians should be aware that DIU predicts beta-cell dysfunction 3-months after islet transplantation.  
This could help appropriately discard donor organs at higher risk of failure and expand the donor pool 
by using organs not exposed to insulin previously considered unsuitable based on donor 
characteristics alone.  
Based on our data, as well as from previous studies, the optimum peri-transplant target 
glucose range is unclear
5
.  In light of our results, we do not support the pursuit of tighter glycaemic 
control during the peri-transplant period, neither do we advocate widening the current target glucose 
range and loosening of glycaemic control. 
 
Strengths and limitations 
Our study has several strengths. First, using data from the entire UK cohort of islet cell 
transplantation, we provide the first description of the relationship between DIU and clinical outcomes.  
Second, we have provided further evidence to support the notion that data on insulin use is a better 
determinant of outcomes than glucose levels alone.   
We acknowledge some limitations: First, we have a modest number of beta-cell function 
outcomes which leads to wide confidence intervals around risk estimates and a limited ability to adjust 
for potential confounders.  Second, our data does not exclude the possibility that insulin therapy on 






beneficial effects of insulin on beta-cells
13
 and because high glucose levels occur on ICU before and 
not after insulin is prescribed. Third, accurate data on donor insulin dosage is not routinely collected.  
Whilst we could not assess the precise relationship between insulin dosage and outcomes, data on 
insulin duration provided an estimated relationship with dosage.  Finally, follow-up was limited to 3-
months because a second islet-infusion from a different donor, routinely occurring at 3-6 months, 
means that outcomes thereafter cannot be attributed to individual donor factors.   
 
Summary 
We provide data supporting the hypothesis that DIU is a predictor of beta-cell dysfunction in islet 
transplant recipients.   Further effort is required to clarify the underlying mechanisms that might lead 
to better transplant outcomes in islet donors and recipients receiving insulin therapy – these 
mechanisms can then be harnessed and applied in the clinical setting as part of the broader aim of 
achieving long-term insulin independence after islet transplantation from a single donor.  Identifying a 
threshold for blood glucose levels or insulin dose requirement associated with a poorer outcome could 
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Table 1: Donor characteristics associated with donor insulin use on 
intensive care in Islet Cell Transplantation 
 
Data are mean ± SD or n (%) or median (IQR) 
BMI, body mass index; DBD, Donation after Brain Death; ICH, Intracranial Haemorrhage; HBI, 
Hypoxic Brain Injury; NA, not applicable 
* White vs non-white ethnicity 
  
Donor variables Donor Insulin Use in intensive care p-value 
 
Yes (n= 52) No (n = 39) 
 
Age, years 46 (10) 45 (10) 0.80 
BMI, kg/m
2
 29 (10) 29.3 (5) 0.48 
Sex (female) 28 (54) 26 (67) 0.53 
Ethnicity     
   White 45 (87) 36 (92) 0.51* 
Smoking  22 (43) 15 (40) 0.83 
Alcohol  5 (10) 2 (5) 1.00 
Hypertension  8 (16) 10 (26) 0.13 
Cardiac disease  2 (4) 5 (13) 0.23 
Cardiac arrest  12 (24) 10 (26) 1.00 
Peri-retrieval hypotension 37 (71) 26 (67) 0.66 
Donor Type (DBD) 46 (89) 33 (85) 0.76 





Trauma 4 (8) 5 (13) 0.49 
 
Meningitis 1 (2) 0 (0) NA 
 
Stroke (thrombo-embolic) 1 (2) 2 (5) NA 
 
ICH 31 (60) 24 (62) 1.00 
 
HBI 9 (17) 3 (8) 0.22 
 
Brain tumour 2 (4) 1 (3) NA 
 
Other 4 (8) 4 (10) NA 
Amylase, U/l 56 (34-115) 54 (37-100) 0.89 
Steroid use 25 (61.0) 33 (64) 0.83 
Islet yield (IEQ/kg) 6193 (2122) 5822 (1695) 0.42 






Table 2: Univariable and multivariable-adjusted β-
coefficients (SE) relating donor insulin use with 3-month 
HbA1c, 90-minute glucose and 90-minute c-peptide during 
meal tolerance testing in islet transplant recipients 




HbA1C (mmol/mol) 5.36 (2.62) 0.04 
 
Fasting glucose (mmol/L) 1.96 (0.92) 0.03 
 
90-min glucose (mmol/L) 2.84 (1.23) 0.02 
 
Fasting c-peptide (pmol/L) -107.90 (46.10) 0.02 
 
90-min c-peptide (pmol/L) -145.00 (106.80) 0.18 
  BETA-2 score -3.53 (1.50) 0.02 
 Insulin reduction -0.04 (0.03) 0.21 
Adjusted for age, BMI and islet yield * 
 
 
HbA1C (mmol/mol) 7.05 (3.08) 0.04 
 
Fasting glucose (mmol/L) 2.44 (0.93) 0.02 
 
90-min glucose (mmol/L) 3.85 (1.40) <0.01 
 
Fasting c-peptide (pmol/L) -100.24 (50.10) 0.05 
 
90-min c-peptide (pmol/L) -117.91 (104.46) 0.26 
  BETA-2 score -3.87 (1.64) 0.02 
 Insulin reduction -5.46 (7.58) 0.47 
The BETA-2 score
8
 is a composite measure of graft function which includes the following data: fasting 
glucose, fasting c-peptide, HbA1c, and insulin dose 
The β coefficients associated with DIU can be interpreted as the 
average difference in the outcome (e.g. HbA1c level) between 
donors treated with insulin and donors not treated with insulin. 
Positive values indicate higher levels in the DIU group 
compared to the no-DIU group 
* Covariates identified in the published literature
 
 
